CTLA4 and neoplasm: Patients that did not respond to anti-CTLA-4 antibody ipilimumab therapy was reported to harbour mutations in the interferon gamma (IFN-γ) pathway genes leading to the ability of the tumour cells to escape from T cells, which was identified as a primary resistance to anti-CTLA-4 therapy (Gao et al., 2016).